Avni Shah

Title: Avni Shah: Innovator in Cancer Treatment

Introduction

Avni Shah is a prominent inventor based in Framingham, MA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of multi-specific binding proteins.

Latest Patents

Avni Shah holds a patent for "Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen." This patent focuses on methods for treating cancer by utilizing multi-specific binding proteins that target NKG2D, CD16, and tumor-associated antigens such as HER2. The disclosure includes the use of these proteins in combination with corticosteroids to minimize the risk of infusion-related reactions. Additionally, it outlines applications for treating cancers with low or moderate HER2 expression levels. The patent also encompasses pharmaceutical formulations that incorporate these multi-specific binding proteins.

Career Highlights

Avni Shah is currently associated with Dragonfly Therapeutics, Inc., where she continues her groundbreaking work in cancer research. Her dedication to developing effective cancer therapies has positioned her as a key figure in the biotechnology industry.

Collaborations

Avni collaborates with notable colleagues, including Jean-Marie Cuillerot and Mark DeRose, to advance her research and enhance the impact of her innovations.

Conclusion

Avni Shah's contributions to cancer treatment through her patented methods and collaborative efforts highlight her role as an influential inventor in the field. Her work continues to pave the way for new therapeutic approaches in oncology.